Vassilios Aslanis

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i> -Mutant Melanoma

Jean‐Pierre Delord, Caroline Robert, Marta Nyakas et al. · Clinical Cancer Research · 2017 · 184 citations · Full text

Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy

Mario Campone, H. Cortés-Funes, Daniel Vorobiof et al. · British Journal of Cancer · 2006 · 53 citations · Full text

An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)

Erin Gaughan, Tom Quinn, Andrew C. Mills et al. · American Journal of Respiratory and Critical Care Medicine · 2022 · 37 citations · Full text

Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants

Vassilios Aslanis, Robert J. Slack, Alison C. MacKinnon et al. · Cancer Chemotherapy and Pharmacology · 2023 · 36 citations · Full text

Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study

Noelle V. Frey, Jun Ho Jang, Jeff Szer et al. · The Lancet Haematology · 2019 · 30 citations · Full text

Hematological Malignancy, Eltrombopag Treatment, Medicine +10